Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Converting a 401k to a retirement plan can be a strategic move. Learn when it's the right time to make that transition.
20,599 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
A marquee Bitcoin treasury deal tied to Adam Back’s 30,021 bitcoin is undergoing a financing overhaul as key backers ...
When markets swing on news and surprises, traders crave flexibility. The cboe global markets launch of extended hours...
Grab's CEO recently sold 400,000 Class A shares for about $1.6 million. This insider move raises the question: should...
Alphabet faces a pivotal year as AI monetization expands and cloud momentum compounds. Traders watch how capital spen...
Tech stocks pulled back this week as margin risk reemerged amid a cooling chip cycle. Investors who bet on leverage w...
Bill Ackman's closed-end fund recently trades at a sizable discount, prompting questions about a Berkshire-style bet....
Investors eye a single ETF as the simplest path for the rest of 2026 amid AI-driven gains and shifting rate expectati...
A year after federal funding ended, South Dakota's public media network stays on air thanks to local support, partner...
As live-music prices climb, the Vans Warped Tour returns with a price-conscience plan. The founder argues fans deserv...
A major fund recently added a sizable Mosaic position, highlighting growing interest in fertilizer stocks as potash p...
AXT Inc. is poised for a pivotal earnings night after a dramatic rally. Look for updates on demand for indium phosphi...